Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals is a biopharmaceutical company that develops and commercializes cardiovascular medicines. Its approved product, CARDAMYST (etripamil) nasal spray, is a prescription treatment for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults and is available in the United States. Milestone also develops etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) and explores other potential therapeutic applications. It sells CARDAMYST through retail pharmacy distribution, using a third-party logistics provider to distribute the packaged product to wholesalers. Its U.S. commercialization work includes a specialty sales force, digital promotion, reimbursement support and patient support. Milestone also seeks marketing approvals outside the United States, including through partners, and pursues strategic collaborations. Its headquarters are in Montreal, Quebec, Canada.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $MIST in the last 7 days.
No SEC Form 4 filings for $MIST in the last 30 days.
See all $MIST insider activity →Nasdaq notified Milestone Pharmaceuticals (MIST) that its shares traded below $1.00 for 30 days, violating listing rules. The company has until April 21, 2027, to comply, with no immediate delisting.
Milestone Pharmaceuticals (MIST) announced the first European patient has been enrolled in its Phase 3 ReVeRA-301 trial for etripamil nasal spray to treat atrial fibrillation with rapid ventricular rate (AFib-RVR). The study, targeting 150 patients, is evaluating the same 70 mg dose approved for PSVT in the U.S. as CARDAMYST. Enrollment is ongoing in the U.S. and Canada.
Milestone Pharmaceuticals (MIST) announced the first Canadian patient enrollment in the ReVeRA-301 Phase 3 trial for etripamil nasal spray, targeting atrial fibrillation with rapid ventricular rate (AFib-RVR). The study aims to enroll 150 patients globally, evaluating the 70 mg dose already FDA-approved for PSVT as CARDAMYST.
Recent MIST coverage spans technology, financial news and regulation.
Potential delisting risk creates downward pressure on the stock.
The enrollment milestone signals progress toward trial completion and potential FDA filing, likely supporting the stock.
First enrollment expands the trial globally, indicating progress toward pivotal data that could support an FDA indication for AFib‑RVR.
Fundamentals suggest further downside pressure.
New product entry expands addressable market.
AlphAI scores every news story that mentions MIST with an AI model for sentiment and relevance, and aggregates insider trades from Milestone Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nasdaq notified Milestone Pharmaceuticals (MIST) that its shares traded below $1.00 for 30 days, violating listing rules. The company has until April 21, 2027, to comply, with no immediate delisting.
Milestone Pharmaceuticals (MIST) announced the first European patient has been enrolled in its Phase 3 ReVeRA-301 trial for etripamil nasal spray to treat atrial fibrillation with rapid ventricular rate (AFib-RVR). The study, targeting 150 patients, is evaluating the same 70 mg dose approved for PSVT in the U.S. as CARDAMYST. Enrollment is ongoing in the U.S. and Canada.
Milestone Pharmaceuticals (MIST) announced the first Canadian patient enrollment in the ReVeRA-301 Phase 3 trial for etripamil nasal spray, targeting atrial fibrillation with rapid ventricular rate (AFib-RVR). The study aims to enroll 150 patients globally, evaluating the 70 mg dose already FDA-approved for PSVT as CARDAMYST.
French AI startup Mistral raised €3B, valuing it at €21B. Milestone Pharmaceuticals (MIST), a biotech firm, has a high P/S ratio of 57.14, weak financials, and insider selling. Investors should exercise caution due to growth assumptions and financial distress signals.
Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.
Milestone Pharmaceuticals (MIST) announced China's approval of etripamil nasal spray for treating PSVT in adults, triggering a $2M milestone payment. Everest Medicines holds exclusive rights in Greater China, with up to $98M in potential milestones and 18% royalties. The approval was based on Phase 3 study data showing significant efficacy over placebo.
Milestone Pharmaceuticals (MIST) began a Phase 3 trial for etripamil nasal spray to treat AFib-RVR. The study aims to assess rapid ventricular rate reduction and symptom improvement in unsupervised settings. MIST seeks FDA approval based on existing safety data. The stock traded between $1.00 and $3.06 in the past year, closing at $1.03 on Thursday.
Milestone Pharmaceuticals (MIST) shares rose 3.9% after enrolling the first patient in its Phase 3 ReVeRA-301 trial for etripamil in treating AFib-RVR. The trial evaluates the same 70 mg dose approved for PSVT. The study aims to enroll 150 patients, with primary and secondary endpoints focused on ventricular rate reduction and symptom improvement. Milestone seeks FDA approval for home use. AFib affects 6 million U.S. patients, with projected economic costs rising to $174.8 billion by 2050, accor
Milestone Pharmaceuticals (MIST) reported Q2 2026 earnings, with product revenue of $559,000 and a net loss of $28.6 million. The company saw a fourfold increase in prescriptions and 50% commercial insurance coverage for CARDAMYST. Management expects cash runway into 2H 2027 and anticipates Medicare coverage in 2027. The Phase III trial for AFib-RVR is underway, targeting a larger patient population.
Milestone Pharmaceuticals (NASDAQ:MIST) reported Q2 product revenue of $0.6M versus none a year earlier, and a net loss of $28.6M ($0.21/share). Management said CARDAMYST prescriber uptake and payer coverage improved, with coverage at about 25% of commercially insured lives and plans to expand. Milestone also started registrational enrollment for ReVeRA-301 etripamil in AFib-RVR.
